Company intelligence / Profile preview

CovX Research

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

CovX was a biopharmaceutical company focused on developing a new class of biotherapeutics called CovX-Bodies. This platform technology involves the site-specific conjugation of pharmacologically active peptides or small molecules to a specialized scaffold antibody, combining the half-life and distribution of an antibody with the potency of a peptide. The company's lead programs targeted metabolic diseases and oncology before it was acquired by Pfizer to bolster its biologics portfolio. Following the acquisition, CovX operated as a specialized research unit within Pfizer's BioTherapeutics Pharmaceutical Sciences group.

Therapeutic areas: OncologyEndocrinologyMetabolic Disorders
Modalities: AntibodyPeptidesRecombinant fusion protein
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on CovX Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CovX Research.

Explore the full profile